Amy L. Kimble

Amy L. Kimble

Auto-generated profile, based on publicly available information

Amy L. Kimble

Department of Cell Biology, Center for Vascular Biology and Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (S.-A.E.N., S.B.H., C.L.P., J.H., A.L.K., B.H., A.R.-O., P.A.M.).

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2025 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
OOOmar M. F. Omar
Omar M. F. Omar
AKAmy L. Kimble
Amy L. Kimble
ACAshok Cheemala
Ashok Cheemala
JTJordan D. Tyburski
Jordan D. Tyburski
SPSwati Pandey
Swati Pandey
PMPatrick A. Murphy
Patrick A. Murphy
Endothelial cells (ECs) help maintain the blood–brain barrier but deteriorate in many neurodegenerative disorders. Here we show, using a specialized method to isolate EC and microglial nuclei from postmortem human cortex (92 donors, 50 male and 42 female, aged 20–98 years), that intranuclear cellular indexing of transcriptomes and epitopes enables simultaneous profiling of nuclear proteins and RNA transcripts at a single-nucleus resolution. We identify a disease-associated subset of capillary ECs in Alzheimer’s disease, amyotrophic lateral sclerosis and frontotemporal degeneration. These capillaries exhibit reduced nuclear β-catenin and β-catenin-downstream genes, along with elevated TNF/NF-κB markers. Notably, these transcriptional changes correlate with the loss of nuclear TDP-43, an RNA-binding protein also depleted in neuronal nuclei. TDP-43 disruption in human and mouse ECs replicates these alterations, suggesting that TDP-43 deficiency in ECs is an important factor contributing to blood–brain barrier breakdown in neurodegenerative diseases.

18 April 2025 in Science Advances
Verified
Journal Article
Open access
ACAshok Cheemala
Ashok Cheemala
AKAmy L. Kimble
Amy L. Kimble
EBEmily N. Burrage
Emily N. Burrage
SHStephen B. Helming
Stephen B. Helming
JTJordan D. Tyburski
Jordan D. Tyburski
PMPatrick A. Murphy
Patrick A. Murphy
Mutations in the TARDBP gene encoding TDP-43 protein are linked to loss of function in neurons and familial frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). We recently identified reduced nuclear TDP-43 in capillary endothelial cells (ECs) of donors with ALS-FTD. Because blood-brain barrier (BBB) permeability increases in ALS-FTD, we postulated that reduced nuclear TDP-43 in ECs might contribute. Here, we show that nuclear TDP-43 is reduced in ECs of mice with an ALS-FTD–associated mutation in TDP-43 ( Tardbp G348C ) and that this leads to cell-autonomous loss of junctional complexes and BBB integrity. Targeted excision of TDP-43 in brain ECs recapitulates BBB defects and loss of junctional complexes and ultimately leads to fibrin deposition, gliosis, phospho-Tau accumulation, and impaired memory and social interaction. Transcriptional changes in TDP-43–deficient ECs resemble diseased brain ECs. These data show that nuclear loss of TDP-43 in brain ECs disrupts the BBB and causes hallmarks of FTD.

1 June 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
SNSarah-Anne E. Nicholas
Sarah-Anne E. Nicholas
SHStephen B. Helming
Stephen B. Helming
AMAntoine Ménoret
Antoine Ménoret
CPChristopher L. Pathoulas
Christopher L. Pathoulas
MXMaria M. Xu
Maria M. Xu
PMPatrick A. Murphy
Patrick A. Murphy
BACKGROUND: Atherosclerotic plaques form through lipid and immune cell accumulation beneath the arterial endothelium. CD8 (cluster of differentiation 8) T cells are abundant in lesions, and their activation correlates with cardiovascular disease severity. Although endothelial cells recruit CD8 T cells to low and disturbed flow regions, whether they regulate CD8 activation and persistence is unknown. These interactions may be mediated by posttranscriptional control of mRNA translation. METHODS: We used ribosomal profiling in Cdh5(PAC ); RiboTRAP mice to assess posttranscriptional regulation in atherosclerotic endothelium in a partial carotid ligation model. We then used CreERT2; Elavl ff; RiboTRAP (endothelial cell–knockout) mice to examine the impact of endothelial Elavl1 (ELAV-like RNA-binding protein 1) on gene expression programs and immune cell activity. RESULTS: Elavl1 motifs were enriched near alternative splicing events, and within 5′ untranslated regions of transcripts with altered ribosomal association in atherosclerosis. Elavl1 suppressed gene expression programs occurring in atherogenic endothelium, as deletion enhanced these responses and reduced CD8 T-cell accumulation (≈70%) at plaques without affecting recruitment, consistent with impaired persistence. In vitro, Elavl1-deficient endothelial cells suppressed antigen-dependent CD8 T-cell persistence, even in the presence of wild-type myeloid antigen-presenting cells and cognate antigen. CONCLUSIONS: Endothelial Elavl1 suppression enables endothelial cells to function as local immune checkpoint–like regulators of CD8 T-cell persistence in atherosclerosis. Thus, endothelial Elavl1 is a key regulator of adaptive immunity.

16 January 2026 in Research Square
Verified
Preprint
Open access
PDF file
TCTimothy Crombleholme
Timothy Crombleholme
KMKristen Moriarty
Kristen Moriarty
SMSanjukta Majumder
Sanjukta Majumder
CKChia-Ling Kuo
Chia-Ling Kuo
AKAmy Kimble
Amy Kimble
OFOna Faye-Petersen
Ona Faye-Petersen
Introduction. Preeclampsia causes severe complications for the mother, fetus, and newborn, yet the underlying mechanisms remain poorly understood. The BPH/5 mouse is the only spontaneous mouse model that recapitulates key features of human preeclampsia. Although impaired angiogenesis and endothelial dysfunction are hallmarks of this disease, the molecular pathways capable of restoring placental vascular integrity remain undefined. Existing animal models of preeclampsia have not directly targeted the placenta. We hypothesized that hIGF-1 rescues placental endothelial function by driving angiogenic gene expression through the IKK-β/NF-κB signaling axis, thereby correcting the maternal pathophysiologic features of preeclampsia. Methods. Placental morphometric analysis for CD31 immunostaining was performed on human placental samples from early onset preeclampsia (EOPE), gestational age-matched preterm premature rupture of membranes (PPROM), and term healthy controls. Next, primary human placental microvascular endothelial cells were cultured to evaluate IGF-1–mediated responses using in vitro angiogenesis assays under normoxic and hypoxic conditions, in the presence or absence of established NF-κB inhibitors. Cell proliferation was assessed using Ki-67 immunostaining and flow cytometry, and PCR-chromatin immunoprecipitation was used to quantify NF-κB binding to promoter regions of angiogenic genes in human placenta vascular endothelial cells as well as BeWo cells. In parallel, BPH/5 and C57BL/6 mice were time-mated and habituated to blood pressure cuff monitoring. Intraplacental gene delivery of 1x10 8 PFU of Ad-hIGF-1 (referred to as Ad-IGF-1) or Ad-LacZ was performed on embryonic day 16 with cerclage, followed by harvest on e21. Maternal endpoints of blood pressure and proteinuria were assessed at non-pregnant, first-trimester, pre-injection, and post-injection time points. Kidney histology, sFlt-1 levels, and placental endothelial microvascular density assessment were evaluated. Fetal endpoints included litter outcomes. Results. Morphometric placental analysis of EOPE vs. term healthy and PPROM controls showed that microvascular density is markedly reduced while villous architecture remains preserved. BPH/5 placentas similarly exhibit reduced microvascular density in comparison to C57BL/6 placentas. Restoration of microvasculature was appreciated after IGF-1 gene transfer. Angiogenesis and proliferation assays in HPVECs demonstrated that IGF-1 robustly enhances both angiogenic activity and cell proliferation under normoxic and hypoxic conditions, primarily through IKKβ/NF-κB–dependent transcriptional activation of key angiogenic genes. Interestingly, IGF-1 was found to enhance NF-κB signal transduction of angiogenic gene promoters in BeWo cells, but not HPVECs. In the BPH/5 mouse, intraplacental gene transfer of IGF-1 reduced the post-injection systolic, diastolic, and mean arterial pressures comparable to C57BL/6 controls, with the SBP consistently reduced at all delta comparisons across timepoints. Urinary protein levels in BPH/5 were also comparable to controls after gene transfer with Ad-IGF-1. Litter size, demise rate, reabsorptions, and pup weight were unaffected by Ad-IGF-1 gene transfer. Ad-IGF-1 treatment reduced glomerulosclerosis (47.2% vs. surgical sham; 58% vs. Ad-LacZ controls) while liver histology and s-Flt-1 were unchanged. Conclusion. IGF-1 gene transfer reverses the preeclampsia-like phenotype in BPH/5 mice by restoring placental microvascular density without affecting fetal outcomes in the first animal model of preeclampsia treatment that directly targets the placenta. Furthermore, IGF-1’s pro-angiogenic effects are suggested to occur via IKKβ/NF-κB–dependent activation.